CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,091 enrolled
Drug / intervention
PF-07321332 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04960202
NCT04960202Phase 3Completed
CompareCT.gov

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS

Pfizer·interventional·Posted Jul 13, 2021·Updated Jul 10, 2025

In Brief

A Phase 3 clinical trial evaluating PF-07321332, Ritonavir, and 1 other intervention for COVID-19. Completed, enrolled 2,091 participants across 201 sites in 20 countries.

Detailed Summary

The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing severe illness. Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or another non-clinic location if available. The total study duration is up to 24 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesArgentina, Brazil, Bulgaria, Colombia, Czechia, Hungary, India, Japan, Malaysia, Mexico, Poland, Puerto Rico, Russia, South Africa, South Korea, Spain, Thailand, Turkey (Türkiye), Ukraine, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedJul 13, 2021
Enrollment StartJul 16, 2021
Primary CompletionDec 9, 2021
Study CompletionApr 25, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.0 years ago

Interventions

PF-07321332drug

PF-07321332 (tablet)

Ritonavirdrug

Ritonavir (capsule)

Placebodrug

Placebo (tablet or capsule)